Takara Holdings (2531) Q2 2026 earnings summary

Executive summary

• Group net sales increased 5.7% year-over-year to ¥186,556 million, led by Takara Shuzo Int'l Group's strong overseas alcoholic beverages and M&A in Japanese food wholesale, while Takara Shuzo and Takara Bio Group saw declines due to prior demand shifts and a weak life science market.

• Operating income for the group decreased 26.1% year-over-year to ¥7,786 million, as gains in the overseas alcoholic beverages business were offset by higher SGA expenses, interest expenses, foreign exchange losses, and declines in other segments.

• Net income attributable to owners of the parent fell 37.3%, impacted by impairment losses at Takara Bio Group, partial reversal of deferred tax assets, and lower operating income, despite extraordinary income from asset sales.

• Compared to forecasts, all major segments underperformed in net sales, and group operating and net income were below expectations.

Financial highlights

• Consolidated net sales: ¥186,556 million (+5.7% YoY), gross profit: ¥61,642 million (+4.9% YoY), operating income: ¥7,786 million (–26.1% YoY), net income attributable to owners: ¥1,491 million (–37.3% YoY).

• Overseas operations (excluding Takara Bio Group) accounted for 62.6% of net sales, up from 58.5% YoY.

• Takara Shuzo: Net sales ¥57,760 million (–6.8% YoY), operating income ¥2,465 million (–6.0% YoY).

• Takara Shuzo Int'l Group: Net sales ¥103,889 million (+16.8% YoY), operating income ¥6,658 million (+2.6% YoY).

• Takara Bio Group: Net sales ¥18,794 million (–4.9% YoY), operating loss ¥2,342 million.

Outlook and guidance

• Group net sales for FY ending March 2026 forecast at ¥392,000 million (+8.1% YoY), operating income ¥16,200 million (–21.3% YoY), net income attributable to owners ¥11,100 million (–31.5% YoY); full-year forecasts were revised downward.

• Takara Shuzo Int'l Group is projected to outperform previous forecasts, while Takara Shuzo and Takara Bio Group are expected to underperform due to weak sales and market stagnation.

• Operating income for the group is projected to decrease, with Takara Bio Group expected to post an operating loss.